Relay Medical, Glow Lifetech Announce Successful Phase II COVID-19 Trials Based On Their Tech

Relay Medical (CSE: RELA) last night announced a positive development related to Glow LifeTech, a private firm in which the company has significant ownership of. Glow has seen a successful phase II clinical trial completed on a COVID-19 treatment candidate, which is based on its MyCell Technology.

Glow’s partner Swiss Pharmacan AG and MGC Pharma announced the full results of the study, which was a phase II double-blind placebo-controlled clinical trial on the anti-inflammatory treatment known as ArtemiC. The treatment is based on Glow’s MyCell technology, which is a delivery system technology that Glow has the exclusive rights license for manufacturing, sales and marketing on certain cannabis and nutraceutical ingredients within North America.

The study successfully met all primary and secondary endpoints within the study, while also demonstrating that it is able to improve the clinical outcome of COVID-19 patients. The study involving 50 patients show that ArtemiC statistically significantly improved the clinical outcome of COVID-19 patients when compared to the placebo group. No patients that received the treatment required additional oxygen, mechanical ventilation, or intensive care, which compares to 23.4% of the placebo group whom did require such additional measures.

“These are very exciting results for Glow’s MyCell Technology™ and the ArtemiC™ formulation. We are pleased that our innovative MyCell Technology™ is helping to power a natural formulation that shows promising ability to improve and expedite the recovery of COVID-19 patients. It demonstrates the long term potential of MyCell Technology™ to power next generation natural health products with science-backed efficacy and safety.”

Clark Kent, CEO of Glow LifeTech

A Phase III clinical trial is now slated to begin in the first half of 2021. The trial is currently identified as being an international multicentre study, which focuses on encompassing a wide range of inflammatory indications for the use of the treatment.

Relay Medical last traded at $0.29 on the CSE.

FULL DISCLOSURE: Relay Medical Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Relay Medical Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply